Literature DB >> 31308193

Association of sirolimus with pericardial effusion in renal transplant patient and discussion of potential mechanism.

Lingbin Meng1, Bo Deng1, Baoqiong Liu1, Dwayne Gordon1.   

Abstract

Sirolimus is an important immunosuppressive drug in renal transplantation but contains numerous side effects. In this study, we describe a case of renal transplant recipient treated with sirolimus who developed pericardial effusion associated with interstitial pneumonia. An extensive search for alternative causes were all negative, and all symptoms disappeared after sirolimus interruption. Therefore, this case demonstrates that sirolimus can cause pericardial effusion possibly through a proinflammatory mechanism. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cardiovascular system; immunological products and vaccines; pericardial disease; renal system

Mesh:

Substances:

Year:  2019        PMID: 31308193      PMCID: PMC6663303          DOI: 10.1136/bcr-2019-230269

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

Review 1.  mTOR--beyond transplantation.

Authors:  Deborah A Young; Cheryl L Nickerson-Nutter
Journal:  Curr Opin Pharmacol       Date:  2005-08       Impact factor: 5.547

Review 2.  Cardiac tamponade and pericardial effusion: respiratory variation in transvalvular flow velocities studied by Doppler echocardiography.

Authors:  C P Appleton; L K Hatle; R L Popp
Journal:  J Am Coll Cardiol       Date:  1988-05       Impact factor: 24.094

3.  Sirolimus immunosuppression in pediatric heart transplant recipients: a single-center experience.

Authors:  Natalia E Lobach; Stacey M Pollock-Barziv; Lori J West; Anne I Dipchand
Journal:  J Heart Lung Transplant       Date:  2005-02       Impact factor: 10.247

4.  Pericardial effusion coincident with sirolimus therapy: a review of Wyeth's safety database.

Authors:  George H Steele; Anthony B Adamkovic; Laura A Demopoulos; Linda C Rothrock; Maureen E Caulfield; Michael D Blum; Charles M Schubert; Dany D Hembekides; Ajay B Singh
Journal:  Transplantation       Date:  2008-02-27       Impact factor: 4.939

5.  Management of side effects of sirolimus therapy.

Authors:  Giovanni Stallone; Barbara Infante; Giuseppe Grandaliano; Loreto Gesualdo
Journal:  Transplantation       Date:  2009-04-27       Impact factor: 4.939

Review 6.  Sirolimus: its discovery, biological properties, and mechanism of action.

Authors:  S N Sehgal
Journal:  Transplant Proc       Date:  2003-05       Impact factor: 1.066

7.  Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies.

Authors:  Timothy Mathew; Henri Kreis; Peter Friend
Journal:  Clin Transplant       Date:  2004-08       Impact factor: 2.863

8.  The TSC-mTOR signaling pathway regulates the innate inflammatory response.

Authors:  Thomas Weichhart; Giuseppina Costantino; Marko Poglitsch; Margit Rosner; Maximilian Zeyda; Karl M Stuhlmeier; Thomas Kolbe; Thomas M Stulnig; Walter H Hörl; Markus Hengstschläger; Mathias Müller; Marcus D Säemann
Journal:  Immunity       Date:  2008-10-09       Impact factor: 31.745

9.  Sirolimus therapy may cause cardiac tamponade.

Authors:  Dominique Bertrand; Geoffroy Desbuissons; Nicolas Pallet; Alain Debure; Albane Sartorius; Dany Anglicheau; Marie-France Mamzer; Christophe Legendre; Rebecca Sberro-Soussan
Journal:  Transpl Int       Date:  2012-11-29       Impact factor: 3.782

10.  Tacrolimus as a Rare Cause of Pericardial Effusion in a Renal Transplant Recipient.

Authors:  Rohini Prashar; Diana Stewart; Ankush Moza
Journal:  Heart Views       Date:  2017 Oct-Dec
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.